[Breaking] Kolon TissueGene (950160) plunged straight to the lower limit at the market open on the 22nd, extending its downward trend for a second consecutive day.

As of 9:04 a.m., Kolon TissueGene is trading at 30,050 won, down 12,850 won (-29.95%) from the previous day. At 9:00:10 a.m., immediately after the market opened, a Volatility Interruption (VI) was triggered, reflecting a concentration of selling pressure.

The previous day, the stock also hit the lower limit at the market open and closed at the price limit. The weakness has not stopped today either.

The plunge is interpreted as the continued fallout from the first topline results of the U.S. Phase 3 clinical trial for 'TG-C,' which failed to meet the pre-defined co-primary efficacy endpoints.

The company stated, "No new clinical safety concerns have been identified, and additional data analysis and the remaining clinical schedule will proceed as planned."

With two consecutive days of hitting the lower limit compounded by a VI trigger early in the session, market caution is widening. With investor sentiment showing little sign of recovery, whether the company can rebuild investor confidence through future clinical data and analysis results is cited as the key variable for a share price turnaround.

[This article is not intended to solicit investment. The final judgment and responsibility for all investments lie with the investor.]